AbbVie Inc. (ABBV) – Other promising aspects of ABBV’s growth

This report is useful for M&A and business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for insights on any specific sector/industry and market recommendations.

AbbVie Inc. (ABBV)

Apart from Humira, ABBV has 11 key drugs which will generate at least $1bn of revenue for FY22. It has a diverse and powerful portfolio of drugs which include, Skyrizi and Rinvoq. These are two key drugs which has contributed towards the revenue growth in Q2FY22.

Highlights

Valuation

– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– PE Band Comparison
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Developments
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

Crispidea Coverage

No of Pages : 40